The Future of Targeted Therapy for Leiomyosarcoma
Ryan A Denu1, Amanda M Dann2, Emily Z Keung3
1Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Abstract:
Leiomyosarcoma (LMS) is an aggressive subtype of soft tissue sarcoma that arises from smooth muscle cells, most commonly in the uterus and retroperitoneum. LMS is a heterogeneous disease with diverse clinical and molecular characteristics that have yet to be fully understood. Molecular profiling has uncovered possible targets amenable to treatment, though this has yet to translate into approved targeted therapies in LMS. This review will explore historic and recent findings from molecular profiling, highlight promising avenues of current investigation, and suggest possible future strategies to move toward the goal of molecularly matched treatment of LMS. We focus on targeting the DNA damage response, the macrophage-rich micro-environment, the PI3K/mTOR pathway, epigenetic regulators, and telomere biology.
Insights
Leiomyosarcoma (LMS) is a complex soft tissue sarcoma. This review explores molecular profiling findings and promising therapeutic targets, including DNA damage response and the tumor microenvironment, for tailored LMS treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Leiomyosarcoma (LMS) is an aggressive soft tissue sarcoma originating from smooth muscle cells.
- LMS is characterized by significant clinical and molecular heterogeneity, hindering effective treatment.
- Despite molecular profiling, targeted therapies for LMS remain largely unapproved.
Purpose of the Study:
- To review historical and recent molecular profiling data in LMS.
- To highlight promising therapeutic targets and current research avenues.
- To propose future strategies for molecularly matched LMS treatment.
Main Methods:
- Comprehensive literature review of molecular profiling studies in LMS.
- Analysis of emerging therapeutic strategies targeting specific molecular pathways.
- Discussion of potential future directions in LMS research.
Main Results:
- Molecular profiling has identified several potential therapeutic targets in LMS.
- Key areas of investigation include DNA damage response, tumor microenvironment, PI3K/mTOR pathway, epigenetic regulation, and telomere biology.
- Translating these findings into approved targeted therapies is an ongoing challenge.
Conclusions:
- Targeting specific molecular pathways holds promise for personalized LMS treatment.
- Further research is needed to validate these targets and develop effective therapies.
- A multi-faceted approach addressing the tumor's molecular complexity is crucial for advancing LMS care.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...